**Supporting paper for JAPC meeting on**

**Document title:**

**Submitted by:**

**Quality and Equality Impact Assessment (QEIA)**

A Quality and Equality Impact Assessment form **must** be completed prior to JAPC ratification for a Do Not Prescribe (DNP) drug classification or where a decommissioning policy has been produced. This is **only** necessary where patients are already on NHS treatment and where there is no suitable alternative treatment, however, JAPC should consider due regard with all recommendations.

***(EIA Protected Characteristic: Age, Disability, Gender Re-assignment, Marriage and Civil Partnership, Pregnancy and Maternity, Race, Religion and Belief, Sex, Sexual Orientation)***

Link to the current version of the QEIA policy and tool <https://intranet.ddicb-nhs.uk/self-service/quality-and-equality-impact-assessment-qeia/>

**Conflicts of interest declaration**

Guideline Group / JAPC members do not need to declare providing that the Annual Conflict of Interest Declaration form has been completed. It will be the responsibility of the JAPC member to inform the secretary within 28 days to notification of status change.

Non-Guideline Group / JAPC members must declare all Conflicts of Interest. If a conflict of interest needs to be declared a form must be completed and submitted with this front sheet*. See* [*Conflicts of Interest Declaration Appendix 1*](http://www.derbyshiremedicinesmanagement.nhs.uk/joint_area_prescribing_committee/japc_templates) *for a detailed definition*.

**Ethical Decision Framework**

JAPC members need to be mindful of the [ICBs Ethical Decision Framework](https://intranet.ddicb-nhs.uk/staff-area/governance/corporate-policies-and-procedures/) and have read, understood, and apply its principals.

**(For CPD to complete)** Are any clinical/shared care guidelines relevant to be sent to the shared care pathology group? Y/N

**Consultees**

|  |  |
| --- | --- |
| **Name or group** | **Designation** |
|  |  |
|  |  |
|  |  |

**Purpose *(reminder: for DNP classification proposal see above re: QEIA)***

**Background**

**Summary**

**Financial Implications**

**Recommendation**

**Decision of JAPC** (JAPC decision based on the balance of: clinical effectiveness, cost effectiveness, patient factors & safety)